Genmab's Darzalex sales in line with estimates but slightly below own forecast
Sales increased 22.5% in the fourth quarter.
af marketwire
Genmab’s partner Johnsons & Johnson has presented sales figures for Darzalex that fall short of its 2023 forecast.
Sales of the cancer treatment rose 22.5% in the fourth quarter to USD 2.55 billion, a point above the analyst consensus gathered by Bloomberg News.
For the quarter, sales in the US increased 22.5% to USD 1395 million, while sales in the rest of the world increased 22.3% to USD 1155 million.
For the full year, Darzalex sales grew 22.2% to USD 9.744 billion. Genmab’s forecast was 9.8-10 billion dollars.
Genmab has developed Darzalex, which is used to treat bone marrow cancer, while Johnson & Johnson has the marketing rights and pays sales commissions to Genmab.
